Stockscreener 앱 받기
1.2096
4.31%
0.0496
Io Biotech Inc 주식(IOBT)의 최신 뉴스
Investors in cash trouble should check out IO Biotech Inc (IOBT) - SETE News
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
IO Biotech (NASDAQ:IOBT) Rating Reiterated by HC Wainwright - Defense World
IO Biotech (NASDAQ:IOBT) PT Raised to $6.00 - Defense World
IO Biotech Inc [IOBT] moved up 3.22: Why It’s Important - The DBT News
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Piper Sandler maintains Overweight rating on IO Biotech shares By Investing.com - Investing.com Canada
Analyzing IO Biotech Inc (IOBT) After Recent Trading Activity - Knox Daily
IOBT (IO Biotech Inc) has impressive results - US Post News
Market Momentum: IO Biotech Inc (IOBT) Registers a -2.20 Decrease, Closing at 0.75 - The Dwinnex
Non Small Cell Lung Cancer Pipeline Insights, Treatment Drugs, Emerging Therapies and Companies 2024 - Barchart
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga
Examining the Potential Price Growth of McDonald’s Corp (MCD) - Knox Daily
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer - Marketscreener.com
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer - StockTitan
IOBT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
IO Biotech Inc’s results are impressive - US Post News
IO Biotech Inc [IOBT] Insider Activity: An Update for Investors - Knox Daily
Ratios in Focus: Analyzing IO Biotech Inc (IOBT)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
IO Biotech stock hits 52-week low at $0.8 amid market challenges - Investing.com Canada
It is Poised to be a Bull Market for IO Biotech Inc (IOBT) - SETE News
Virtual SymposiumHarnessing the Power of Immuno-Modulating Vaccines in Cancer Treatment - PRIME® Continuing Medical Education
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
Checking in on Ionis Pharmaceuticals Inc (IONS) after recent insiders movement - Knox Daily
Taking a Closer Look At Gitlab Inc (GTLB) Following Its Recent Trade - Knox Daily
IOBT (IO Biotech Inc) may reap gains as insiders became active recently - Knox Daily
Before You Invest, Make Sure You Check This IO Biotech Inc (NASDAQ: IOBT) Analysis - Stocks Register
General Mills, Inc. [GIS] Insider Shaffer Werner Lanette sells 710 Shares - Knox Daily
IO Biotech (NASDAQ:IOBT) Receives “Buy” Rating from HC Wainwright - Defense World
IO Biotech’s (IOBT) Overweight Rating Reaffirmed at Piper Sandler - Defense World
IO Biotech (NASDAQ:IOBT) Given New $4.00 Price Target at Morgan Stanley - Defense World
IO Biotech (NASDAQ:IOBT) Stock Rating Reaffirmed by Piper Sandler - MarketBeat
Morgan Stanley Cuts IO Biotech (NASDAQ:IOBT) Price Target to $4.00 - MarketBeat
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher - Benzinga
Nasdaq Dips Over 2%; US Construction Spending Falls In JulySify Technologies (NASDAQ:SIFY) - Benzinga
IO Biotech shares target cut by Jefferies, retains Buy rating - Investing.com Canada
Gaining Ground: IO Biotech Inc (IOBT) Closes Lower at 1.50, Down -2.60 - The Dwinnex
Investing in IO Biotech Inc (IOBT) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
IO Biotech shares hold as trial continues, Buy rating affirmed By Investing.com - Investing.com UK
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Marketscreener.com
IO Biotech’s melanoma treatment trial to continue after IDMC review - Yahoo Finance
Top 5 AI & Digital Biotech Companies (September 2024) - Securities.io
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - ForexTV.com
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Marketscreener.com
IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Marketscreener.com
TEDCO Fuels Biotech Innovation in Maryland: Key Investments in NEOPATHOLOGY CORP. and Simmbion, LLC at FITCI - BioBuzz
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Increases By 56.6% - MarketBeat
IO Biotech Announces Participation in Upcoming Investor Conferences - Marketscreener.com
IO Biotech Announces Participation in Upcoming Investor Conferences - StockTitan
IOBTIO Biotech, Inc. Latest Stock News & Market Updates - StockTitan
private equity firms who own 59% along with institutions invested in IO Biotech, Inc. (NASDAQ:IOBT) saw increase in their holdings value last week - Simply Wall St
IO Biotech Inc [IOBT] stock was sold by Novo Holdings A/S at the price of US$68339.0 - Knox Daily
IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024 - MSN
IO Biotech (NASDAQ:IOBT) Stock Rating Reaffirmed by HC Wainwright - Defense World
Genentech to shut down cancer immunology research department amid broader R&D rethink - Fierce Biotech
HC Wainwright Analysts Lower Earnings Estimates for IO Biotech, Inc. (NASDAQ:IOBT) - MarketBeat
IO Biotech (NASDAQ:IOBT) Announces Earnings Results - Defense World
The Potential Rise in the Price of IO Biotech Inc (IOBT) following insiders activity - Knox Daily
IO Biotech (NASDAQ:IOBT) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
IO Biotech (NASDAQ:IOBT) Rating Reiterated by HC Wainwright - MarketBeat
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights - BioSpace
IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024 - InvestorPlace
IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024 - TradingView
IO Biotech : Corporate Deck August 2024 - Marketscreener.com
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights - ForexTV.com
IO Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights - Marketscreener.com
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights - wallstreet:online
1.07%
2.16%
자본화:
|
볼륨(24시간):